• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Mendelsohn Alan was granted 35,193 shares, increasing direct ownership by 17,596% to 35,393 units

    8/22/23 7:45:20 PM ET
    $TMBR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TMBR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mendelsohn Alan

    (Last) (First) (Middle)
    C/O TIMBER PHARMACEUTICALS, INC.
    3 MOUNTAINVIEW RD, SUITE 100

    (Street)
    WARREN NJ 07059

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Timber Pharmaceuticals, Inc. [ TMBR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & CMO
    3. Date of Earliest Transaction (Month/Day/Year)
    08/20/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 08/20/2023 A 35,193(1) A $0 35,393 D
    Common Stock, par value $0.001 per share 39 I By spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On August 20, 2023, the Reporting Person was granted 35,193 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.001. 25% of the RSUs vest on August 20, 2024, and the remaining RSUs vest in 36 equal monthly installments beginning on September 20, 2024, as long as the Reporting Person remains in continuous service with the Issuer through each vesting date; provided, however, that the RSUs will vest in full in the event that a "Change in Control" (as defined in the Issuer's 2020 Omnibus Incentive Plan) occurs while the Reporting Person remains in continuous service with the Issuer.
    /s/ Joseph Lucchese, Power of Attorney 08/22/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TMBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMBR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TMBR
    Financials

    Live finance-specific insights

    See more
    • Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

      - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022. John Koconi

      3/31/23 4:28:34 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

      -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2022, ended September 30, 2022. John Koconis, Chairman and Chie

      11/14/22 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

      Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter of 2022, ended March 31, 2022. John Koconis, Chairman and Chief Executive Officer of Timber, commented, "Timber's lead asset, TMB-001, continues to progress following the receipt of Fast Track designation late last month, w

      5/12/22 4:10:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

      WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its

      11/29/23 5:26:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

      WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt

      11/28/23 5:21:07 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

      WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)

      9/18/23 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    SEC Filings

    See more
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/26/24 8:00:46 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/22/24 7:21:51 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      12/22/23 4:12:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Timber Pharmaceuticals Inc.

      SC 13G - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      8/15/22 6:01:57 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/14/22 9:40:54 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/4/22 3:39:18 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

      LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

      3/25/22 7:30:00 AM ET
      $ACST
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors

      - Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Chief Executive Officer John Koconis has been appointed as Chairman of the Board of Directors. The Company also announced that Edward J. Sitar has been appointed as Lead Independent Director of the Board and David Cohen, M.D., will

      4/23/21 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

      Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.  “We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn

      1/25/21 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koconis John was granted 70,385 shares, increasing direct ownership by 17,596% to 70,785 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:46:54 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Mendelsohn Alan was granted 35,193 shares, increasing direct ownership by 17,596% to 35,393 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:45:20 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lucchese Joseph was granted 35,193 shares

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:43:35 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care